Abstract
A fundamental problem in cancer research is identification of the cells responsible for tumor formation. The latest field of cancer research has revealed the existence and role of cancer stem cells (CSCs). These findings support the idea that malignancies originate from a small fraction of cancer cells that show self-renewal and multi- or pluripotency. Identification of this CSC population has important implications for the management of cancer patients, including diagnostic and predictive laboratory assays as well as novel therapeutic strategies that specifically target CSCs. In this study, we investigated the growth rates of CSC populations for comparison with cancer cell lines. To construct the growth curves, blood-derived CSCs were isolated from patients with breast, colon, or lung cancer and cultured in vitro. Quantitative real-time PCR was then performed to identify CSCs in the samples. We found that CSCs did not follow the common pattern of a typical growth curve of mammalian cells in contrast to the cancer cell lines. This observation of rapidly growing CSCs indicates their involvement in tumor formation.
Keywords: Cancer stem cells, growth curves, Nanog, Oct3/4, Sox2.
Current Stem Cell Research & Therapy
Title:Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Volume: 9 Issue: 2
Author(s): Maria Toloudi, Eleni Ioannou, Marina Chatziioannou, Panagiotis Apostolou, Christos Kiritsis, Stella Manta, Dimitrios Komiotis and Ioannis Papasotiriou
Affiliation:
Keywords: Cancer stem cells, growth curves, Nanog, Oct3/4, Sox2.
Abstract: A fundamental problem in cancer research is identification of the cells responsible for tumor formation. The latest field of cancer research has revealed the existence and role of cancer stem cells (CSCs). These findings support the idea that malignancies originate from a small fraction of cancer cells that show self-renewal and multi- or pluripotency. Identification of this CSC population has important implications for the management of cancer patients, including diagnostic and predictive laboratory assays as well as novel therapeutic strategies that specifically target CSCs. In this study, we investigated the growth rates of CSC populations for comparison with cancer cell lines. To construct the growth curves, blood-derived CSCs were isolated from patients with breast, colon, or lung cancer and cultured in vitro. Quantitative real-time PCR was then performed to identify CSCs in the samples. We found that CSCs did not follow the common pattern of a typical growth curve of mammalian cells in contrast to the cancer cell lines. This observation of rapidly growing CSCs indicates their involvement in tumor formation.
Export Options
About this article
Cite this article as:
Toloudi Maria, Ioannou Eleni, Chatziioannou Marina, Apostolou Panagiotis, Kiritsis Christos, Manta Stella, Komiotis Dimitrios and Papasotiriou Ioannis, Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells, Current Stem Cell Research & Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574888X0902140121163539
DOI https://dx.doi.org/10.2174/1574888X0902140121163539 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Polymeric Micelles of Modified Chitosan Block Copolymer as Nanocarrier for Delivery of Paclitaxel
Current Nanomedicine Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
Current Pharmaceutical Design Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Mogroside V Inhibits Hyperglycemia-induced Lung Cancer Cells Metastasis through Reversing EMT and Damaging Cytoskeleton
Current Cancer Drug Targets Extracellular Citrate in Health and Disease
Current Molecular Medicine Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Mini-Reviews in Medicinal Chemistry Synthesis and Antiproliferative Activity of New Coumarin-Based Benzopyranone Derivatives Against Human Tumor Cell Lines
Medicinal Chemistry 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety